London, UK – [Insert Date] – Kyverna Therapeutics is poised to potentially secure a groundbreaking first-to-market therapy for Stiff-Person Syndrome (SPS), a rare and debilitating autoimmune neurological disorder. Recent Phase III trial data for their investigational CAR-T therapy, miv-cel (mivocabtagene autoleucel), has demonstrated sustained and significant improvements in patients, offering a beacon of hope in a therapeutic landscape currently devoid of FDA-approved treatments. The promising results, particularly from the KYSA-8 study, are set to be incorporated into Kyverna’s rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA), signaling a significant step towards regulatory approval.
n
The Unmet Need: A Devastating Disease with No Approved Therapies
n
Stiff-Person Syndrome (SPS) is a rare, progressive, and profoundly disabling autoimmune neurological disorder characterized by severe muscle stiffness, rigidity, and excruciatingly painful spasms. These symptoms typically manifest in the trunk, abdomen, and limbs, progressively impairing mobility and quality of life. While the syndrome’s rarity means it affects a small percentage of the population, its public profile has risen in recent years, notably with the public diagnosis of global superstar Céline Dion in 2022, bringing much-needed attention to this often-overlooked condition.
n
The current therapeutic landscape for SPS is starkly limited. There are no FDA-approved drugs specifically indicated for the treatment of SPS. Management strategies often involve off-label use of medications such as benzodiazepines to manage spasms and muscle stiffness, alongside immunomodulatory therapies. However, these approaches frequently offer only partial relief and do not address the underlying autoimmune attack driving the disease. The pipeline for novel SPS therapies is equally sparse, underscoring the critical need for innovative treatment modalities.
n
This void in approved therapies creates an immense unmet medical need and presents a significant opportunity for companies like Kyverna Therapeutics, whose miv-cel therapy is showing remarkable potential to become the first approved treatment for SPS.
n
A Closer Look at the Promising Data: KYSA-8 Trial Highlights
n
The cornerstone of Kyverna’s optimism lies in the compelling data emerging from the Phase III KYSA-8 study (NCT06588491), a registrational trial designed to evaluate the efficacy and safety of miv-cel in patients with SPS. The study’s primary and secondary endpoints were met at the 16-week mark, as confirmed at the American Academy of Neurology (AAN) Annual Meeting held in April 2026. However, the recently released one-year data has further solidified the therapy’s potential.
n
Key Findings from the KYSA-8 Study at 12 Months:
n
- n
- Sustained Mobility Improvement: Patients treated with miv-cel experienced a sustained 49% improvement in their timed 25-Foot Walk (T25FW) at month 12. This represents a significant and durable enhancement compared to the 46% improvement observed at the earlier 16-week assessment. The T25FW is a crucial measure of ambulatory function, and improvements in this metric directly translate to enhanced daily living capabilities for SPS patients.
- Near-Healthy Mobility Achieved: Remarkably, more than one-third of patients in the study were able to complete the T25FW in less than 5 seconds. This benchmark is comparable to the typical walking time of healthy adults, indicating a profound restoration of motor function for a substantial portion of the treated cohort.
- Durability of Benefit: The sustained nature of the improvements is particularly noteworthy. Of the patients who achieved a clinically meaningful improvement in their T25FW at the primary analysis, an impressive 95% maintained their gains at the 12-month mark. This suggests that miv-cel may offer long-lasting therapeutic effects, a critical factor for a progressive neurological disorder.
- Well-Tolerated Safety Profile: Miv-cel, an anti-CD19 CAR-T therapy engineered to stimulate CD28, demonstrated a favorable safety profile throughout the study. Crucially, there were no instances of high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Furthermore, no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were reported. This robust safety profile is paramount for a therapy intended for chronic conditions and adds to the therapy’s potential for broad patient acceptance.
n
n
n
n
n
A Chronological Journey Towards a Potential Breakthrough
n
Kyverna Therapeutics has been diligently advancing its CAR-T therapy for autoimmune diseases, with SPS as a key focus. The journey of miv-cel from preclinical development to promising late-stage clinical data can be traced through several key milestones:
n
- n
- Early Development & Preclinical Research: Kyverna’s commitment to leveraging CAR-T technology for autoimmune disorders laid the groundwork for their SPS program. Preclinical studies demonstrated the potential of targeting CD19-expressing B cells, which are implicated in the autoimmune attack characteristic of SPS.
- Phase I/II Trials: Initial clinical studies likely established the foundational safety and preliminary efficacy signals for miv-cel in SPS patients, informing the design of subsequent larger trials.
- KYSA-8 Study Initiation: The Phase III KYSA-8 study was initiated to rigorously assess the efficacy and safety of miv-cel in a larger patient population, aiming to gather the pivotal data required for regulatory submission.
- 16-Week Data Presentation (April 2026): Kyverna presented the initial positive results from the KYSA-8 study at the American Academy of Neurology (AAN) Annual Meeting. This presentation confirmed that the study met its primary and secondary endpoints at 16 weeks, generating significant excitement within the neurology and rare disease communities.
- One-Year Data Unveiled: The subsequent release of one-year follow-up data from the KYSA-8 study has provided even more robust evidence of miv-cel’s sustained efficacy and favorable safety profile. These longer-term results are critical for demonstrating the durable benefit of the therapy.
- Rolling BLA Submission: Armed with this compelling one-year data, Kyverna Therapeutics is now poised to incorporate these findings into its rolling Biologics License Application (BLA) submission to the FDA. This strategic approach allows for the submission of data as it becomes available, potentially accelerating the review process.
n
n
n
n
n
n
n
Supporting Data and Expert Endorsement
n
The robust clinical data from the KYSA-8 study is further bolstered by the insights and endorsements of leading experts in the field. Dr. Amanda Piquet, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine and the Celine Dion Foundation endowed chair, who also served as the lead investigator of the KYSA-8 trial, offered a strong endorsement of the findings.
n
Dr. Piquet commented, "The results from KYSA-8 are compelling, particularly given the severe burden of SPS and the absence of approved therapies. After a single dose of miv-cel, the sustained improvements observed in mobility, stiffness, and other disease-specific measures, together with a well-tolerated profile, underscore its potential to deliver significant, long-lasting benefit to patients with SPS."
n
Her statement highlights the critical aspects of Kyverna’s therapy: its ability to address the core symptoms of SPS, its sustained impact, and its acceptable safety profile, all of which are crucial in a disease with such profound functional impairment and limited treatment options.
n
Regulatory Pathway and Future Implications
n
The upcoming rolling BLA submission to the FDA marks a pivotal moment for Kyverna Therapeutics and, more importantly, for individuals living with SPS. By proactively submitting data as it becomes available, Kyverna aims to streamline the regulatory review process. The success of this submission would not only validate years of research and development but also establish miv-cel as the first FDA-approved therapy for SPS, a significant achievement in the rare disease space.
The potential approval of miv-cel carries profound implications:
- Transformative Treatment for SPS Patients: A first-in-class therapy could fundamentally change the management of SPS, offering patients a tangible hope for symptom relief, improved mobility, and a better quality of life. The sustained benefits observed in the KYSA-8 trial suggest a potential for long-term disease modification, not just symptomatic management.
- Advancement in Autoimmune CAR-T Therapy: The success of miv-cel in SPS would further solidify the role of CAR-T therapy in treating autoimmune diseases, a field that is rapidly evolving. This could pave the way for similar approaches in other challenging autoimmune conditions.
- Market Opportunity: While the SPS patient population is small, the significant unmet need and the absence of competition create a substantial market opportunity. Kyverna’s first-mover advantage, if secured, would be a considerable commercial success.
- Broader Impact on Rare Disease Research: The development of a successful therapy for SPS could inspire further investment and innovation in research for other rare neurological and autoimmune disorders.
Parallel Progress in Generalized Myasthenia Gravis (gMG)
In addition to the promising SPS data, Kyverna Therapeutics also shared encouraging longer-term results from its Phase II/III KYSA-6 study of miv-cel in generalized myasthenia gravis (gMG). Analysis of up to 18 months of data from the Phase II portion revealed that all seven patients achieved clinically meaningful improvements in both the Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at 24 weeks. These improvements were sustained at the one-year mark for those who had been receiving treatment for that duration. MG-ADL and QMG are also the co-primary endpoints for the ongoing Phase III portion of this study.
This parallel progress in gMG further underscores the potential of miv-cel as a versatile therapeutic agent for a range of autoimmune conditions. The gMG market is substantial, projected to reach $13 billion by 2034 across seven major markets, according to a GlobalData market forecast report. Kyverna’s advancements in this area, alongside their SPS program, position the company as a significant player in the autoimmune therapeutics landscape.
Conclusion
Kyverna Therapeutics’ miv-cel is demonstrating remarkable potential to become the first FDA-approved treatment for Stiff-Person Syndrome. The sustained efficacy and favorable safety profile observed in the Phase III KYSA-8 trial, particularly the one-year data, offer a profound sense of optimism for patients and clinicians alike. As Kyverna moves forward with its rolling BLA submission, the prospect of a transformative therapy for this debilitating rare disease is closer than ever, potentially ushering in a new era of treatment for SPS and further validating the power of CAR-T therapy in the autoimmune space.
